These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17112427)

  • 1. Treatment of children with osteogenesis imperfecta.
    Rauch F; Glorieux FH
    Curr Osteoporos Rep; 2006 Dec; 4(4):159-64. PubMed ID: 17112427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F; Glorieux FH
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the evaluation and treatment of osteogenesis imperfecta.
    Harrington J; Sochett E; Howard A
    Pediatr Clin North Am; 2014 Dec; 61(6):1243-57. PubMed ID: 25439022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E; Chlebna-Sokół D
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review.
    Sinikumpu JJ; Ojaniemi M; Lehenkari P; Serlo W
    Injury; 2015 Aug; 46(8):1440-6. PubMed ID: 25943292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteogenesis imperfecta: practical treatment guidelines.
    Antoniazzi F; Mottes M; Fraschini P; Brunelli PC; Tatò L
    Paediatr Drugs; 2000; 2(6):465-88. PubMed ID: 11127846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy for severe osteogenesis imperfecta.
    Glorieux FH
    J Pediatr Endocrinol Metab; 2000 Sep; 13 Suppl 2():989-92. PubMed ID: 11086652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern approach to children with osteogenesis imperfecta.
    Zeitlin L; Fassier F; Glorieux FH
    J Pediatr Orthop B; 2003 Mar; 12(2):77-87. PubMed ID: 12584489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
    Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
    Zacharin M; Bateman J
    J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteogenesis imperfecta: diagnosis and treatment.
    Palomo T; Vilaça T; Lazaretti-Castro M
    Curr Opin Endocrinol Diabetes Obes; 2017 Dec; 24(6):381-388. PubMed ID: 28863000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenesis imperfecta: new treatment options.
    Chevrel G; Cimaz R
    Curr Rheumatol Rep; 2006 Dec; 8(6):474-9. PubMed ID: 17092446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.